This paper argues that “ASEA redox Supplement” (ARS) may show comparable or even stronger beneficial effects (with less or none adverse effects) than corticosteroids in children with Duchenne Muscular Dystrophy (DMD) and Becker muscular dystrophy (BMD). This paper presents a third case report on the effects of an ionized “saline water” called “ASEA redox Supplement®” (ARS) oral solution in a ~3-year-old boy with DMD from town Slobozia [URL2], Romania. In vitro studies showed that ARS is a very potent selective NRF2 activator, thus a very potent (indirect) antioxidant and cytoprotective: the studies conducted in vivo also support this main pharmacological mechanism of ARS, with no toxicity up to high doses, in contrast with the much more toxic corticosteroids. From the first months of ARS treatment, the main rhabdomyolysis markers (with very high initial serum levels) dropped significantly, with no found toxicity until the present. Before starting adjuvant therapy with oral ARS, this boy-patient was already prescribed by his attending neurologist a combined therapy with: L-carnitine (1g/day) & Vitamin D3 (1000IU/day) & calcium-magnesium oral supplement (5ml/day) & plant-extracts hepatoprotective syrup (5ml/day) & coenzyme Q10 (30mg/day) from the last week of February 2019 (thus from approximately 5 months earlier than the moment in which ARS therapy was initiated). This previous combined therapy of dietary supplements (DSs) also showed a promising decrease in rhabdomyolysis serum markers (RSMs) (which is also an important fact with implications for other children with DMD who may potentially benefit from this combined set of DSs): however, when the calcium-magnesium oral supplement was replaced by a combination of ARS (30ml/day ~ 2.5ml/kg/day) & omega-3 fatty acids (185mg/day with a DHA: EPA ratio of approx. 5-to-1) from August 1st, 2019, the RSMs decrease was quite spectacular (when compared to the anterior decrease) when measured in December 2nd, 2019 at “Victor Gomoiu” Pediatric Hospital (from Bucharest, Romania). This paper continues the work of other past articles/preprints of the same author.